Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.

塞库金单抗 医学 银屑病 银屑病面积及严重程度指数 安慰剂 注射器 随机对照试验 内科学 皮肤病科 病理 精神科 替代医学 银屑病性关节炎
作者
Alice B. Gottlieb,Andrew Blauvelt,Jörg C. Prinz,P. Papanastasiou,Rashidkhan Pathan,Judit Nyirady,Todd Fox,C. Papavassilis
出处
期刊:PubMed 卷期号:15 (10): 1226-1234 被引量:30
链接
标识
摘要

Secukinumab, a human monoclonal antibody that selectively targets interleukin-17A, is highly efficacious in the treatment of moderate-to-severe psoriasis, starting at early time points, with a sustained effect and a favorable safety profile.Patients with moderate-to-severe plaque psoriasis were randomized to secukinumab 300 mg, secukinumab 150 mg, or placebo self-administered by prefilled syringe at baseline, weeks 1, 2, and 3, and then every four weeks from week 4 to 48. Efficacy responses (≥ 75/90/100% improvement in Psoriasis Area and Severity Index [PASI 75/90/100] and clear/almost clear skin by Investigator's Global Assessment 2011 modified version [IGA mod 2011 0/1]) were measured to week 52. Patient-reported usability of the prefilled syringe was evaluated by the Self-Injection Assessment Questionnaire to week 48.The efficacy of secukinumab increased to week 16 and was maintained to week 52. With secukinumab 300 mg at week 52, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 83.5%/68.0%/47.5% and 71.5% of patients when analyzed by multiple imputation, respectively, and by 75.9%/62.1%/43.1% and 63.8% of patients when analyzed by nonresponder imputation, respectively. With secukinumab 150 mg at week 52, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 63.5%/50.3%/31.1% and 43.6% of patients when analyzed by multiple imputation, respectively, and by 61.0%/49.2%/30.5% and 42.4% of patients when analyzed by nonresponder imputation, respectively. Self-reported acceptability of the prefilled syringe was high throughout the study. The incidence of adverse events (AE) was well balanced between groups, with AEs reported in 74.4% of patients receiving secukinumab 300 mg and 77.3% of patients receiving secukinumab 150 mg. Nasopharyngitis was the most common AE across both secukinumab groups.Self-administration of secukinumab by prefilled syringe was associated with robust and sustained efficacy and a favorable safety profile up to week 52.

J Drugs Dermatol. 2016;15(10):1226-1234.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
某博完成签到 ,获得积分10
2秒前
3秒前
5秒前
555完成签到,获得积分10
6秒前
7秒前
科研通AI2S应助Jaylen采纳,获得10
8秒前
李爱国应助孤独树叶采纳,获得10
9秒前
9秒前
格子布发布了新的文献求助10
10秒前
KKK完成签到,获得积分20
11秒前
lyjj023发布了新的文献求助30
12秒前
彩色半烟发布了新的文献求助10
13秒前
14秒前
踏实芝麻完成签到,获得积分10
15秒前
Hello应助abcd_1067采纳,获得10
17秒前
17秒前
共享精神应助Jian采纳,获得10
19秒前
科研通AI2S应助科研通管家采纳,获得10
20秒前
NPC应助科研通管家采纳,获得20
20秒前
酷波er应助科研通管家采纳,获得10
20秒前
20秒前
20秒前
爆米花应助LI采纳,获得10
22秒前
ljforever完成签到,获得积分10
23秒前
24秒前
夜月残阳完成签到,获得积分10
27秒前
28秒前
Lucas应助格子布采纳,获得10
28秒前
sweet完成签到 ,获得积分20
29秒前
曾梦发布了新的文献求助10
29秒前
寒冷妙梦发布了新的文献求助10
30秒前
31秒前
小鱼儿发布了新的文献求助10
31秒前
31秒前
恍恍惚惚完成签到,获得积分10
32秒前
32秒前
abcd_1067发布了新的文献求助10
35秒前
ccc完成签到,获得积分10
40秒前
42秒前
小鱼儿完成签到,获得积分10
42秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
COSMETIC DERMATOLOGY & SKINCARE PRACTICE 388
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3141384
求助须知:如何正确求助?哪些是违规求助? 2792400
关于积分的说明 7802329
捐赠科研通 2448585
什么是DOI,文献DOI怎么找? 1302633
科研通“疑难数据库(出版商)”最低求助积分说明 626650
版权声明 601237